Dogecoin Cash, Inc 10-Q/A for FY2022 Q3
Dogecoin Cash, Inc. (DOGP)
About this 10-Q/A
Dogecoin Cash, Inc filed this 10-Q/A on December 13, 2022, covering the quarter ended September 30, 2022 (FY2022 Q3).
Headline figures
Quarter ended September 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $383.08K
- down 17.3% from $463.04K a year earlier
- Net loss
- $86.63K
- compared with a net loss of $1.15M a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM
———————
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
|
|
For the quarterly period ended: | |
or | |
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
|
|
For the transition period from: _____________ to _____________
Commission File Number: | |
(Exact name of registrant as specified in its charter) |
| ||
(State or Other Jurisdiction |
| (I.R.S. Employer |
of Incorporation) |
| Identification No.) |
(Address of Principal Executive Office) (Zip Code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name, former address, and former fiscal year, if changed since last report)
———————
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered. |
None |
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☐ | Smaller reporting company | ||
Emerging growth company |
|
|
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
The number of shares of the issuer’s Common Stock outstanding as of November 11, 2022, is
EXPLANATORY NOTE
The sole purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the period ended September 30, 2022, filed with the Securities and Exchange Commission on November 14, 2022, is to correct the cover page of the XBRL (eXtensible Business Reporting Language) where the Company was erroneously tagged as a Shell Company. No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q. Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
CANNABIS SATIVA, INC. |
|
Contents |
|
| Page |
|
FINANCIAL STATEMENTS (Unaudited) – for the three and nine months ended September 30, 2022 and 2021: |
|
|
|
|
|
|
|
| FS - 2 |
| |
|
|
|
|
| FS - 3 |
| |
|
|
|
|
Condensed consolidated statements of changes in stockholders’ equity |
| FS - 4 |
|
|
|
|
|
| FS - 5 |
| |
|
|
|
|
| FS – 6 through FS – 13 |
|
| FS - 1 |
| Table of Contents |
CANNABIS SATIVA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED |
|
| September 30, |
|
| December 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
ASSETS |
|
|
|
|
|
| ||
Current Assets |
|
|
|
|
|
| ||
Cash |
| $ |
|
| $ |
| ||
Investment in equity securities, at fair value |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Current Assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Other Assets |
|
|
|
|
|
|
|
|
Right of use asset |
|
|
|
|
|
| ||
Property and equipment, net |
|
|
|
|
|
| ||
Intangible assets, net |
|
|
|
|
|
| ||
Goodwill |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Assets |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
| $ |
|
| $ |
| ||
Operating lease liability, current |
|
|
|
|
|
| ||
Accrued interest - related parties |
|
|
|
|
|
| ||
Convertible note payable |
|
|
|
|
|
| ||
Notes payable to related parties |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Current Liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Long-term liabilities |
|
|
|
|
|
|
|
|
Operating lease liability, long term |
|
|
|
|
|
| ||
Stock payable |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Notes 6 and 8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity: |
|
|
|
|
|
|
|
|
Preferred stock $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
Common stock $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
Additional paid-in capital |
|
|
|
|
|
| ||
Accumulated deficit |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Total Cannabis Sativa, Inc. Stockholders’ Equity (Deficit) |
|
|
|
|
| ( | ) | |
|
|
|
|
|
|
|
|
|
Non-Controlling Interests |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Stockholders’ Equity |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders’ Equity |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements. | ||||||||
| FS - 2 |
| Table of Contents |
CANNABIS SATIVA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED |
|
| Three Months Ended |
|
| Nine Months Ended |
| ||||||||||
|
| September 30, |
|
| September 30, |
|
| September 30, |
|
| September 30, |
| ||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Revenues |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Wages and salaries |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Advertising |
|
|
|
|
|
|
|
|
|
|
|
| ||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from Operations |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (Income) and Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized (gain) loss on investment |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
(Gain) loss on sale of investment securities |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Other (Income) Expenses, Net |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Before Income Taxes |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income Taxes |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss From Continuing Operations |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) from Discontinued Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss on discontinued operations |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Gain on sale of subsidiaries |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) from Discontinued Operations |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss attributable to non-controlling interest - GK Manufacturing |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Loss attributable to non-controlling interest - iBudTender |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Income (loss) attributable to non-controlling interest - PrestoCorp |
|
| ( | ) |
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss for the Period Attributable To Cannabis Sativa, Inc. |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss for the Period per Common Share: Basic & Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
From continuing operations |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
From discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares Outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic & Diluted |
|
|
|
|
|
|
|
|
|
|
|
| ||||
| ||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements. |
| FS - 3 |
| Table of Contents |
CANNABIS SATIVA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 and 2021- UNAUDITED |
|
| Preferred Stock |
|
| Common Stock |
|
| Additional Paid-In |
|
| Accumulated |
|
| Non-controlling Interest - |
|
| Non- controlling Interest - |
|
| Non-controlling Interest - GK |
|
|
| |||||||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Prestocorp |
|
| iBudTender |
|
| Manufacturing |
|
| Total |
| ||||||||||
Balance - July 1, 2021 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||||
Conversion of Preferred to Common |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| — |
|
|
|
|
|
|
|
|
|
| |||||||
Shares issued for services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Net loss for the period |
|
| — |
|
|
|
|
|
| — |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2021 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - July 1, 2022 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||||
Conversion of preferred to common (1:1) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Net income (loss) for the period |
|
| — |
|
|
|
|
|
| — |
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
| ( | ) | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2022 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ | 2,307,738 |
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - January 1, 2021 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
| ||||||||
Conversion of preferred to common |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Cash proceeds from sale of stock |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
Shares issued for services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Cancellation of shares issued for services |
|
| — |
|
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||||
Sale of non controlling interest |
|
| — |
|
|
|
|
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| |||||||
Net income (loss) for the period |
|
| — |
|
|
|
|
|
| — |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) |
|
| ( | ) |
|
| ( | ) | ||||
Balance - September 30, 2021 |
|
|
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - January 1, 2022 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||||
Conversion of preferred to common (1:1) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Conversion of preferred to common (19:1) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Shares issued for services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
Shares issued in consideration of notes and accrued interest payable |
|
| — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
Net income (loss) for the period |
|
| — |
|
|
|
|
|
| — |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
| ( | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2022 |
|
|
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
|
| $ |
|
| $ | 2,307,738 |
| ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
| FS - 4 |
| Table of Contents |
CANNABIS SATIVA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED |
For the nine months ended September 30, |
| 2022 |
|
| 2021 |
| ||
|
|
|
|
|
|
| ||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
| ||
Net loss for the period |
| $ | ( | ) |
| $ | ( | ) |
Adjustments to reconcile net loss for the period to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Unrealized (gain) loss on investment |
|
| ( | ) |
|
|
| |
Gain on sale of investment securities |
|
|
|
|
| ( | ) | |
Gain on sale of subsidiaries |
|
|
|
|
| ( | ) | |
Depreciation and amortization |
|
|
|
|
|
| ||
Stock issued for services |
|
|
|
|
|
| ||
Stock payable for services |
|
|
|
|
|
| ||
Note payable issued for services |
|
|
|
|
|
| ||
Write off of abandoned equipment |
|
|
|
|
|
| ||
Changes in Assets and Liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
| ( | ) | |
Inventories |
|
|
|
|
|
| ||
Prepaid consulting and other current assets |
|
|
|
|
| ( | ) | |
Accounts payable and accrued expenses |
|
|
|
|
|
| ||
Accrued interest - related parties |
|
|
|
|
|
| ||
Customer deposits |
|
|
|
|
|
| ||
Net Cash Used in Operating Activities |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
Cash purchase of equipment |
|
| ( | ) |
|
|
| |
Cash transferred on sale of non-controlling interest |
|
|
|
|
| ( | ) | |
Proceeds from sale of subsidiaries |
|
|
|
|
|
| ||
Net Cash Provided by (Used in) Investing Activities |
|
| ( | ) |
|
|
| |
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
Proceeds from sale of stock |
|
|
|
|
|
| ||
Proceeds from advances from related parties |
|
|
|
|
|
| ||
Proceeds from related parties notes payable, net |
|
|
|
|
|
| ||
Proceeds from convertible note payable |
|
|
|
|
|
| ||
Net Cash Provided by Financing Activities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
NET CHANGE IN CASH |
|
|
|
|
| ( | ) | |
|
|
|
|
|
|
|
|
|
CASH AT BEGINNING OF PERIOD |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
CASH AT END OF PERIOD |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Non Cash Activities: |
|
|
|
|
|
|
|
|
Noncash investing and financing activities: |
|
|
|
|
|
|
|
|
Shares issued in consideration of notes and interest payable |
| $ |
|
| $ |
| ||
Operating lease liability from acquiring right to use asset |
| $ |
|
| $ |
| ||
Sale of Minority Interests Stock Received |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements. | ||||||||
| FS - 5 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
1. Organization and Summary of Significant Accounting Policies
Nature of Business:
Cannabis Sativa, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including:
| · | PrestoCorp, Inc. (“PrestoCorp”) |
| · | Wild Earth Naturals, Inc. (“Wild Earth”) |
| · | Kubby Patent and Licenses Limited Liability Company (“KPAL”) |
| · | Hi Brands, International, Inc. (“Hi Brands”) |
| · | Eden Holdings LLC (“Eden”). |
| · | iBudtender, Inc. (“iBud”) – through April 2021 |
| · | GK Manufacturing and Packaging, Inc. (“GKMP”) - through April 2021 |
PrestoCorp is a
Our primary operations for the years ended December 31, 2021 and through September 30, 2022 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.
Basis of Presentation
Operating results for the three and nine months ended September 30, 2022 may not be indicative of the results expected for the full year ending December 31, 2022. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2021, as filed with the United States Securities and Exchange Commission on April 14, 2022.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2022, and its results of operations, cash flows, and changes in stockholders’ equity for the three and nine months ended September 30, 2022. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.
Principles of Consolidation:
The condensed consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. On April 22, 2021, we sold our interests in two companies in which the Company had majority control, iBud and GKMP. These condensed consolidated financial statements include operations of iBud and GKMP through April 22, 2021. All significant inter-company balances have been eliminated in consolidation.
| FS - 6 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
Going Concern:
The Company has an accumulated deficit of $
Use of Estimates:
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.
Net Loss per Share:
Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the three and nine months ended September 30, 2022 and 2021, the Company had
Recent Accounting Pronouncement:
Accounting Standards Updates Adopted
In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.
Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.
| FS - 7 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
2. Intangibles and Goodwill
The Company considers all intangibles to be definite-lived assets with lives of
|
| September 30, |
|
| December 31, |
| ||
| 2022 |
| 2021 |
| ||||
CBDS.com website (Cannabis Sativa) |
| $ |
|
| $ |
| ||
Intellectual Property Rights (PrestoCorp) |
|
|
|
|
|
| ||
Patents and Trademarks (KPAL) |
|
|
|
|
|
| ||
Total Intangibles |
|
|
|
|
|
| ||
Less: Accumulated Amortization |
|
| ( | ) |
|
| ( | ) |
Net Intangible Assets |
| $ |
|
| $ |
| ||
Amortization expense for each of the three and nine months ended September 30, 2022 and 2021 were $
Amortization of intangibles through 2027 is:
October 1, 2022 to September 30, 2023 |
| $ |
| |
October 1, 2023 to September 30, 2024 |
|
|
| |
October 1, 2024 to September 30, 2025 |
|
|
| |
October 1, 2025 to September 30, 2026 |
|
|
| |
October 1, 2026 to September 30, 2027 |
|
|
|
Goodwill in the amount of $
3. Sale of Majority Owned Subsidiaries and Discontinued Operations
On April 22, 2021, the Company sold its majority interests in GKMP (
The sale of the Company’s majority interests was undertaken to allow the Company to focus on its other operating subsidiary, PrestoCorp, to focus on capital formation for expansion of PrestoCorp, and to pursue other opportunities. At the time of the sale, iBud was inactive and GKMP had not yet achieved positive cash flow from operations.
On the closing date of the sale, CBDG common shares closed at $
| FS - 8 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
During the nine months ended September 30, 2021, the Company recognized a gain on sale of subsidiaries of $
Consideration received: |
|
|
| |
Common stock of CBDG, fair value |
| $ |
| |
Preferred stock of CBDG, fair value |
|
|
| |
Total consideration |
|
|
| |
|
|
|
|
|
Non-controlling interests |
|
| ( | ) |
|
|
|
|
|
Net assets of subsidiaries on date of disposition: |
|
|
|
|
GKMP |
|
|
| |
iBud |
|
| ( | ) |
Net assets |
|
|
| |
Gain on sale of subsidiaries |
| $ |
| |
As a result of the sale, the Company has discontinued its operations for both subsidiaries. Summaries of the discontinued operations of GKMP and iBud for the period January 1, 2021 to September 30, 2021 are provided below.
|
| January 1 to |
| |
|
| September 30, |
| |
Discontinued Operations | 2021 |
| ||
REVENUE |
|
|
| |
Cost of revenues |
|
|
| |
Gross profit |
|
| ( | ) |
EXPENSES |
|
|
|
|
Depreciation and amortization |
|
|
| |
Wages and salaries |
|
|
| |
Advertising |
|
|
| |
General and administrative |
|
|
| |
Interest expense |
|
|
| |
Total expenses |
|
|
| |
NET LOSS FROM DISCONTINUED OPERATIONS |
|
| ( | ) |
GKMP and iBud generated losses from operations during the periods they were operated by the Company. The sale of our interests in GKMP and iBud was to allow management to devote more resources to PrestoCorp.
4. Related Party Transactions
In addition to items disclosed in Notes 3 and 7, the Company had additional related party transactions during the three and nine months ended September 30, 2022 and 2021.
The Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company’s outstanding shares.
| FS - 9 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
During the nine months ended September 30, 2022, David Tobias loaned $
During the three and nine months ended September 30, 2022 and 2021, the Company recorded interest expense related to notes payable to related parties at the rates between
The following tables reflect the related party notes payable balances.
|
| Related party notes |
|
| Accrued interest |
|
| Total |
| |||
|
| September 30, 2022 |
| |||||||||
David Tobias, CEO & Director |
| $ |
|
| $ |
|
| $ |
| |||
New Compendium, greater than 10% Shareholder |
|
|
|
|
|
|
|
|
| |||
Cathy Carroll, Director |
|
|
|
|
|
|
|
|
| |||
Other Affiliates |
|
|
|
|
|
|
|
|
| |||
Totals |
| $ |
|
| $ |
|
| $ |
| |||
|
| Related party notes |
|
| Accrued interest |
|
| Total |
| |||
|
| December 31, 2021 |
| |||||||||
David Tobias, CEO & Director |
| $ |
|
| $ |
|
| $ |
| |||
New Compendium, greater than 10% Shareholder |
|
|
|
|
|
|
|
|
| |||
Cathy Carroll, Director |
|
|
|
|
|
|
|
|
| |||
Other Affiliates |
|
|
|
|
|
|
|
|
| |||
Totals |
| $ |
|
| $ |
|
| $ |
| |||
During the nine months ended September 30, 2022, the Company issued
In the three and nine months ended September 30, 2022 and 2021, the Company incurred approximately $-
| FS - 10 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
5. Investments
At September 30, 2022 and December 31, 2021, the Company owns
In 2021, the Company received
The Company’s investment in CBDG represents
6. Convertible Note Payable
On August 25, 2022, the Company entered into an agreement with 1800 Diagonal Lending, LLC (“Diagonal”) whereby the Company issued convertible note to Diagonal with a principal amount of $
7. Stockholders’ Equity
Change in Authorized Shares
The Company increased the number of authorized common shares the Company is authorized to issue to
| FS - 11 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
Securities Issuances
During the nine months ended September 30, 2022, shares of common stock and preferred stock were issued to related and non-related parties for the purposes indicated, as follows:
|
| Share Issuances in the Nine Months Ended September 30, 2022 |
| |||||||||
Services |
| Common |
|
| Preferred |
|
| Value |
| |||
Related Parties |
|
|
|
|
|
|
|
|
| |||
David Tobias, Officer, Director |
|
| - |
|
|
|
|
| $ |
| ||
Brad Herr, Officer, Director |
|
|
|
|
| - |
|
|
|
| ||
Robert Tankson, Director |
|
|
|
|
| - |
|
|
|
| ||
Trevor Reed, Director |
|
|
|
|
| - |
|
|
|
| ||
Total related party issuances |
|
|
|
|
|
|
|
|
| |||
Non-related party issuances |
|
|
|
|
| - |
|
|
|
| ||
Total shares for services |
|
|
|
|
|
|
|
|
| |||
Shares issued in consideration of notes and accrued interest - related parties |
|
|
|
|
| - |
|
|
|
| ||
Conversion of preferred to common (1:1) |
|
|
|
|
| ( | ) |
|
| - |
| |
Conversion of preferred to common (19:1) |
|
|
|
|
| ( | ) |
|
| - |
| |
Aggregate Totals |
|
|
|
|
| ( | ) |
| $ |
| ||
During the nine months ended September 30, 2021, shares of common stock and preferred stock were issued to related and non-related parties for the purposes indicated, as follows:
|
| Share Issuances in the Nine Months Ended September 30, 2021 |
| |||||||||
Services |
| Common |
|
| Preferred |
|
| Value |
| |||
Related Parties |
|
|
|
|
|
|
|
|
| |||
David Tobias, Officer, Director |
|
| - |
|
|
|
|
| $ |
| ||
Brad Herr, Officer, Director |
|
|
|
|
| - |
|
|
|
| ||
Robert Tankson, Director |
|
|
|
|
| - |
|
|
|
| ||
Cathy Carroll, Director |
|
|
|
|
|
|
|
|
|
| ||
Trevor Reed, Director |
|
|
|
|
| - |
|
|
|
| ||
Total related party issuances |
|
|
|
|
|
|
|
|
| |||
Non-related party issuances |
|
|
|
|
| - |
|
|
|
| ||
Total shares for services |
|
|
|
|
|
|
|
|
| |||
Preferred stock converted to common |
|
|
|
|
| ( | ) |
|
| - |
| |
Issuance for cash |
|
|
|
|
| - |
|
|
|
| ||
Shares cancelled |
|
| ( | ) |
|
| - |
|
|
| ( | ) |
Aggregate Totals |
|
|
|
|
| ( | ) |
| $ |
| ||
During the nine months ended September 30, 2021, the Company cancelled shares that had been returned after it was determined the shares have been erroneously issued to a vendor in 2020.
During the nine months ended September 30, 2022, two preferred shareholders agreed to convert an aggregate of
| FS - 12 |
| Table of Contents |
CANNABIS SATIVA, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For the Three and Nine Months Ended September 30, 2022 and 2021 |
Stock payable at September 30, 2022 consists of
8. Commitments and Contingencies
Leases.
PrestoCorp leased office space through WeWork in New York on a month-to-month arrangement. On April 12, 2022, PrestoCorp signed a new lease in New York with Spaces for a
From October 1, 2022 to September 30, 2023 |
| $ |
| |
From October 1, 2023 to September 30, 2024 |
|
|
| |
Less imputed interest |
|
| ( | ) |
Net lease liability |
|
|
| |
Current Portion |
|
| ( | ) |
Long-term portion |
| $ |
|
Litigation.
In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of September 30, 2022, no claims are outstanding.
9. Other Matters - Merger
On August 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with MJ Harvest, Inc. (“MJHI”). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger. The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the fourth quarter of calendar year 2022. The terms of the Merger Agreement are summarized below:
| · | The name of the surviving company in the Merger will be Cannabis Sativa, Inc. |
| · | Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock. |
| · | The Merger is subject to majority approval of the shareholders of both MJHI and CBDS. |
| · | The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares. |
| · | The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Brad Herr, Randy Lanier, Clinton Pyatt, and David Tobias. |
| · | The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer and Clinton Pyatt - Chief Operating Officer. |
| · | The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature. |
| · | No brokerage fees are payable in connection with the Merger. |
| · | If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated. |
| · | All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs. |
| FS - 13 |
| Table of Contents |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Certain statements in this Report constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms, and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Results of Operations
Prior to April 22, 2021, the Company operated two business segments: PrestoCorp, Inc. (“PrestoCorp”), a telehealth business, and GK Manufacturing and Packaging, Inc. (“GKMP”), a contract manufacturing business. On April 22, 2021, the Company sold its controlling interest in GKMP. The discontinued operations of GKMP are reported separately, below. Discussion of results of operations includes the consolidated results of PrestoCorp.
Three Months Ended September 30, 2022, compared with the Three Months Ended September 30, 2021
|
| Three Months Ended |
| |||||||||||||
|
| A |
|
| B |
|
| A-B |
| |||||||
|
| September 30, 2022 |
|
| September 30, 2021 |
|
| Change |
|
| Change % |
| ||||
REVENUE |
| $ | 383,079 |
|
| $ | 463,040 |
|
| $ | (79,961 | ) |
|
| -17 | % |
Cost of revenues |
|
| 149,943 |
|
|
| 174,814 |
|
|
| (24,871 | ) |
|
| -14 | % |
Cost of sales % of total sales |
|
| 39 | % |
|
| 38 | % |
|
| 1 | % |
|
|
|
|
Gross profit |
|
| 233,136 |
|
|
| 288,226 |
|
|
| (55,090 | ) |
|
| -19 | % |
Gross profit % of sales |
|
| 61 | % |
|
| 62 | % |
|
| -1 | % |
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
| 208,515 |
|
|
| 132,315 |
|
|
| 76,200 |
|
|
| 58 | % |
Depreciation and amortization |
|
| 39,440 |
|
|
| 42,700 |
|
|
| (3,260 | ) |
|
| -8 | % |
Wages and salaries |
|
| 188,622 |
|
|
| 179,136 |
|
|
| 9,486 |
|
|
| 5 | % |
Advertising |
|
| 1,599 |
|
|
| 47,044 |
|
|
| (45,445 | ) |
|
| -97 | % |
General and administrative |
|
| 177,658 |
|
|
| 259,451 |
|
|
| (81,793 | ) |
|
| -32 | % |
Total operating expenses |
|
| 615,834 |
|
|
| 660,646 |
|
|
| (44,812 | ) |
|
| -7 | % |
NET LOSS FROM CONTINUING OPERATIONS |
|
| (382,698 | ) |
|
| (372,420 | ) |
|
| (10,278 | ) |
|
| 3 | % |
Revenues declined 17% in the three months ended September 30, 2022, compared to the three months ended September 30, 2021. Revenues in our fiscal third quarter decreased primarily due to a slow-down in the number of patients seeking medical marijuana cards when compared to year earlier period which saw a significant uptick in activity due to the pandemic. Activity levels in the third quarter of 2022 more closely matched our historic operating levels. We do not anticipate a significant spike in patients seeking our services due to pandemic effects, but the impact of the delta and other variants of the virus cannot be determined at this time.
| 2 |
Gross profit margins for our services, as a percentage of sales, were essentially unchanged in the three months ended September 30, 2022, compared with the same period a year earlier. Holding our gross profit percentages unchanged despite an 17% decline in revenues is attributable to our efforts to control costs at all operating levels.
Total operating costs decreased significantly in the third quarter of 2022 compared to the same period in 2021. We substantially reduced advertising, and general and administrative costs. The cost decreases were primarily the result of our efforts to limit losses while exploring acquisition and growth activities. Our targeted acquisition activities did not result in consummated transactions in the three months ended September 30, 2022, but the Company did sign a letter of intent to Merge with MJ Harvest, Inc. on April 29, 2022, and the Company signed the definitive Merger Agreement on August 8, 2022. The Merger is expected to be completed early in the fourth quarter and, if completed, will provide new business opportunities for the Company.
Net operating loss for the three-month period ended September 30, 2022 increased 3% compared to net loss for the three-month period ended September 30, 2021. The increase in our net operating loss was primarily the result of the decrease in sales.
Nine Months Ended September 30, 2022, compared with the Nine Months Ended September 30, 2021
|
| Nine Months Ended |
| |||||||||||||
|
| A |
|
| B |
|
| A-B |
| |||||||
|
| September 30, 2022 |
|
| September 30, 2021 |
|
| Change |
|
| Change % |
| ||||
REVENUE |
| $ | 1,262,868 |
|
| $ | 1,452,279 |
|
| $ | (189,411 | ) |
|
| -13 | % |
Cost of revenues |
|
| 479,173 |
|
|
| 553,236 |
|
|
| (74,063 | ) |
|
| -13 | % |
Cost of sales % of total sales |
|
| 38 | % |
|
| 38 | % |
|
| 0 | % |
|
|
|
|
Gross profit |
|
| 783,695 |
|
|
| 899,043 |
|
|
| (115,348 | ) |
|
| -13 | % |
Gross profit % of sales |
|
| 62 | % |
|
| 62 | % |
|
| 0 | % |
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees |
|
| 419,923 |
|
|
| 453,236 |
|
|
| (33,313 | ) |
|
| -7 | % |
Depreciation and amortization |
|
| 124,147 |
|
|
| 128,463 |
|
|
| (4,316 | ) |
|
| -3 | % |
Wages and salaries |
|
| 559,533 |
|
|
| 516,534 |
|
|
| 42,999 |
|
|
| 8 | % |
Advertising |
|
| 33,128 |
|
|
| 280,475 |
|
|
| (247,347 | ) |
|
| -88 | % |
General and administrative |
|
| 534,022 |
|
|
| 855,637 |
|
|
| (321,615 | ) |
|
| -38 | % |
Total operating expenses |
|
| 1,670,753 |
|
|
| 2,234,345 |
|
|
| (563,592 | ) |
|
| -25 | % |
NET LOSS FROM CONTINUING OPERATIONS |
|
| (887,058 | ) |
|
| (1,335,302 | ) |
|
| 448,244 |
|
|
| -34 | % |
Revenues declined 13% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. Revenues in the first nine months of 2022 decreased primarily due to a slow-down in the number of patients seeking medical marijuana cards when compared to year earlier period which saw a significant uptick in activity due to the pandemic. Activity levels in the first nine months of 2022 more closely matched our historic operating levels. We do not anticipate a significant spike in patients seeking our services due to pandemic effects, but the impact of the delta and other variants of the virus cannot be determined at this time.
Gross profit margins for our services, as a percentage of sales, were essentially unchanged in the nine months ended September 30, 2022, compared with the same period a year earlier. Holding our gross profit percentages unchanged despite an 13% decline in revenues is attributable to our efforts to control costs at all operating levels.
| 3 |
Total operating costs decreased significantly in the first nine months of 2022 compared to the same period in 2021. We substantially reduced professional fees, advertising, and general and administrative costs. The cost decreases were primarily the result of our efforts to limit losses while exploring acquisition and growth activities. Our targeted acquisition activities did not result in consummated transactions in the nine-month period ended September 30, 2022, but the Company did sign a letter of intent to Merge with MJ Harvest, Inc. on April 29, 2022 and the Company signed the definitive Merger Agreement on August 8, 2022. The Merger is expected to be completed early in the fourth quarter and, if completed, will provide new business opportunities for the Company.
Net operating loss for the nine-month period ended September 30, 2022 decreased 34% compared to net loss for the nine-month period ended September 30, 2021. The decrease in our net operating loss was primarily the result of cost containment efforts pending completion of the Merger with MJ Harvest, Inc.
Discontinued Operations.
In April 2021, the Company entered into discussions with THC Farmaceuticals, Inc. (“CBDG”) regarding sale of CBDS’s controlling interest positions in GKMP and iBudtender Inc. (iBud”). The discussions were triggered by an interest on the part of CBDS management to refocus business efforts on growing PrestoCorp while streamlining financial reporting and management processes by eliminating assets that are no longer considered essential to the Company’s core focus. The sale was completed on April 22, 2021. Management believes that the sale of GKMP and iBud will free up management time and resources to seek other acquisitions that are more closely aligned with the Company’s business model. Consideration for the sale of the controlling interests consisted of 1,500,000 shares of CBDG common stock and 1,500,000 shares of CBDG preferred stock valued at $600,000 on the date of the acquisition. iBud had no revenues in the periods presented. Summaries of the discontinued operations of GKMP and the operations of iBud through April 22, 2021 are provided below.
|
| Period Ended |
| |
Discontinued Operations |
| April 22, 2021 |
| |
REVENUE |
|
| 75,866 |
|
Cost of revenues |
|
| 91,316 |
|
Cost of sales % of total sales |
|
| 120 | % |
Gross profit |
|
| (15,450 | ) |
Gross profit % of sales |
|
| -20 | % |
OPERATING EXPENSES |
|
|
|
|
Depreciation and amortization |
|
| 5,861 |
|
Wages and salaries |
|
| 106,224 |
|
Advertising |
|
| 1,693 |
|
General and administrative |
|
| 102,833 |
|
Interest expense |
|
| 2,144 |
|
Total operating expenses |
|
| 218,755 |
|
NET LOSS FROM DISCONTINUED OPERATIONS |
|
| (234,205 | ) |
GKMP and iBud generated losses from operations during the periods they were operated by the Company. In the second quarter of 2021, management determined that the time and effort required to turn these businesses around would be a significant drain on resources and would limit expansion of our PrestoCorp operations. The sale of our interests in GKMP and iBud eliminates this concern.
Liquidity and Capital Resources
Net cash used in operating activities for the nine-month period ended September 30, 2022, was $120,730. During the same period, our cash position increased by $20,470. Financing activities generated $142,790 in the nine months from related party notes payable.
| 4 |
We also reported stock-based compensation of $350,507 during the nine-month period from issuance of common stock and preferred stock as compensation for services performed by officers, directors, and contractors. On September 30, 2022, our cash position was $214,530. The overhead related to our status as a public company and our continuing efforts to acquire businesses that will supplement the operations of PrestoCorp will continue to generate consolidated losses from operations in the coming periods. Given our level of operations in the first nine months of 2022, we expect that additional funds will be required. In the remainder of 2022, we expect to generate additional capital primarily from issuances of stock as compensation for services.
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses attributable to Cannabis Sativa, Inc. of $505,520 and $1,978,717, respectively, for the nine-month periods ended September 30, 2022 and 2021, and had an accumulated deficit of $79,984,982 as of September 30, 2022. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.
Management is currently evaluating fund-raising alternatives including private placement of equity securities, a secondary public offering, and various debt instruments. In addition, key members of management have indicated a willingness to provide additional operating capital from time to time. We are also currently selling a portion of our investment securities to generate cash for operations, and we have restructured our intercompany loans to PrestoCorp with a monthly amortization schedule and required monthly payments that will begin to address ongoing operating expenses that must be paid in cash. Based on all these considerations, we believe we will have sufficient capital to operate the business for the next twelve months. It will be important for the Company to be successful in its efforts to raise capital if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
In the event the Company consummates the Merger with MJ Harvest, Inc., it is expected that the nature of the business, the cash flow, and access to additional operating capital, will change. The effect of the of the change and the impact on future operations cannot be determined at this time.
COVID-19
COVID-19 has been declared a pandemic by the World Health Organization and the Centers for Disease Control and Prevention. Its rapid spread around the world and throughout the United States prompted many countries, including the United States, to institute restrictions on travel, public gatherings, and certain business operations. These restrictions significantly disrupted economic activity in the United States and Worldwide. The Delta variant of the COVID-19 virus now appears to be creating another wave of infections and concerns about the virus’ impact on business operations continues. To date, the disruption did not materially impact the Company’s financial statements. The pandemic has had a positive impact on the telehealth business. If the severity of the economic disruptions increase as the duration of the COVID-19 pandemic continues, the negative financial impact due to reduced demand could be significantly greater in future periods.
In addition, the economic disruptions caused by COVID-19 could also adversely impact the impairment risks for certain long-lived assets, equity method investments and goodwill. Management evaluated these impairment considerations and determined that no such impairments occurred through the date of this report.
| 5 |
Off Balance Sheet Arrangements
None
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not required.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Conclusions of Management Regarding Effectiveness of Disclosure Controls and Procedures
At the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operations of the Company’s disclosure controls and procedures (as defined in Rule 13a – 15(e) and Rule 15d – 15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective as it was determined that there were material weaknesses affecting our disclosure controls and procedures.
Management of the Company believes that these material weaknesses are due to the small size of the company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting during the quarter ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 6 |
PART II – OTHER INFORMATION
Item 1. Legal Proceedings. We are not a party to any material legal proceedings, and, to the best of our knowledge, no such legal proceedings have been threatened against us.
Item 1A. Risk Factors. Not required.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None.
Item 3. Defaults Upon Senior Securities. None.
Item 4. Mine Safety Disclosures. Not applicable.
Item 5. Other Information. None.
| 7 |
Item 6. Exhibits. The following documents are included as exhibits to this report:
(a) Exhibits
Exhibit Number | SEC Reference Number |
| Title of Document |
3.1 | 3 |
| |
3.2 | 3 | ||
| |||
| |||
101.INS |
|
| XBRL Instance Document |
101.SCH |
| XBRL Taxonomy Extension Schema | |
101.CAL |
|
| XBRL Taxonomy Extension Calculation Linkbase |
101.DEF |
| XBRL Taxonomy Extension Definition Linkbase | |
101.LAB |
|
| XBRL Taxonomy Extension Label Linkbase |
101.PRE |
|
| XBRL Taxonomy Extension Presentation Linkbase |
| |||
XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement, prospectus or other document to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document. |
| 8 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cannabis Sativa, Inc.
Date: November 14, 2022
By: | /s/ David Tobias |
|
| David Tobias, CEO |
|
| (Principal Executive, Financial and Accounting Officer) |
|
| 9 |
EXHIBIT 31.1
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, David Tobias, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Cannabis Sativa, Inc. (the “Registrant”) for the quarter ended September 30, 2022; | |
|
|
|
|
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
|
|
|
|
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report; | |
|
|
|
|
| 4. | The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: | |
|
|
|
|
|
| a)
| designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
| b)
| Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
| c)
| evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
| d) | disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and |
|
|
|
|
| 5. | The Registrant’s other certifying officer(s) and I have disclosed to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions); | |
|
|
|
|
|
| a)
| all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
|
|
| b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting. |
|
|
|
|
| Date: November 14, 2022 | By: | /s/ David Tobias |
| |
|
|
| CEO (Principal Executive, Financial and Accounting Officer) |
| |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cannabis Sativa, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2022, as filed with the Commission on the date hereof (the “Quarterly Report”), I, David Tobias, Principal Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Quarterly Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
| (2) | The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
Dated: November 14, 2022
| /s/ David Tobias |
|
| David Tobias, CEO |
|
| (Principal Executive, Financial and Accounting Officer) |
|